Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Profit After Tax (2016 - 2025)

ProQR Therapeutics' Profit After Tax history spans 5 years, with the latest figure at -$10.4 million for Q4 2025.

  • On a quarterly basis, Profit After Tax fell 4.42% to -$10.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$47.6 million, a 58.44% decrease, with the full-year FY2025 number at -$49.1 million, down 65.51% from a year prior.
  • Profit After Tax hit -$10.4 million in Q4 2025 for ProQR Therapeutics, up from -$12.9 million in the prior quarter.
  • Over the last five years, Profit After Tax for PRQR hit a ceiling of $20.9 million in Q4 2021 and a floor of -$23.5 million in Q3 2022.
  • Historically, Profit After Tax has averaged -$8.8 million across 5 years, with a median of -$10.2 million in 2024.
  • Biggest five-year swings in Profit After Tax: soared 74.89% in 2023 and later plummeted 375.55% in 2025.
  • Tracing PRQR's Profit After Tax over 5 years: stood at $20.9 million in 2021, then crashed by 165.03% to -$13.6 million in 2022, then skyrocketed by 56.52% to -$5.9 million in 2023, then crashed by 68.55% to -$9.9 million in 2024, then decreased by 4.42% to -$10.4 million in 2025.
  • Business Quant data shows Profit After Tax for PRQR at -$10.4 million in Q4 2025, -$12.9 million in Q3 2025, and -$13.8 million in Q2 2025.